PD-1 Non-Small Cell Lung Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight

DelveInsight's, "PD-1 Non-Small Cell Lung Cancer Pipeline Insight" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer pipeline landscape. It covers the PD-1 Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the PD-1 Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive PD-1 Non-Small Cell Lung Cancer pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive PD-1 Non-Small Cell Lung Cancer Pipeline Report to explore emerging therapies, key PD-1 Non-Small Cell Lung Cancer Companies, and future PD-1 Non-Small Cell Lung Cancer treatment landscapes @ PD-1 Non-Small Cell Lung Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the PD-1 Non-Small Cell Lung Cancer Pipeline Report

* In January 2025:- AstraZeneca:- This is a first-time-in-human (FTIH), open-label, multicenter, multi-part, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics, and efficacy of rilvegostomig (AZD2936) in adult participants with stage III unresectable or stage IV NSCLC. The study includes 4 parts: Part A (dose escalation) and Parts B-E (dose expansion).
* In January 2025:- BioAtla Inc.:- This is a multi-center, open-label, Phase 2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC), alone and in combination with PD-1 inhibitor in patients with metastatic non-small cell lung cancer (NSCLC).
* In January 2025:- Incyte Corporation:- The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
* In January 2025:- Merck Sharp & Dohme LLC:- The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with unresected stage I or II (Stage IIB N0, M0) non-small cell lung cancer (NSCLC).
* In January 2025:- Gilead Sciences- The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC).
* DelveInsight's PD-1 Non-Small Cell Lung Cancer pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for PD-1 Non-Small Cell Lung Cancer treatment.
* The leading PD-1 Non-Small Cell Lung Cancer Companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others.
* Promising PD-1 Non-Small Cell Lung Cancer Therapies such as AZD2936, Pembrolizumab 200 mg, Cisplatin, Carboplatin, Durvalumab (MEDI4736 ), and others.

Discover how the PD-1 Non-Small Cell Lung Cancer treatment paradigm is evolving. Access DelveInsight's in-depth PD-1 Non-Small Cell Lung Cancer Pipeline Analysis for a closer look at promising breakthroughs @ PD-1 Non-Small Cell Lung Cancer Clinical Trials and Studies [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

PD-1 Non-Small Cell Lung Cancer Emerging Drugs Profile

* Zimberelimab: Arcus Biosciences

Zimberelimab is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody being developed by Gloria Biosciences, Arcus Biosciences and Taiho Pharmaceutical Co. for the treatment of various cancers including cervical cancer, non-small cell lung cancer and classical Hodgkin's lymphoma. Based on the results of a phase II trial, zimberelimab was recently approved for marketing in China as treatment for relapsed or refractory classical Hodgkin's lymphoma. Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit. The most advanced study with zimberelimab is in Phase III development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic.

* PM8002: Biotheus

PM8002 is a bispecific antibody candidate with humanized anti-PD-L1 single heavy-chain variable (VHH) domains fused to an anti-VEGF-A IgG1 antibody containing Fc-silencing mutations. PM8002 had demonstrated a positive safety profile and encouraging antitumor activity presumably through reduced systemic toxicity by enriching anti-VEGF activity into the tumor microenvironment at ASCO Annual Meeting and ESMO Congress 2023. Currently, the drug is in Phase II/III stage of its clinical trial for the treatment of NSCLC.

* RPH075: R-Pharm

R-Pharm's pembrolizumab biosimilar, known as RPH 075, is a monoclonal antibody classified under antineoplastics, antivirals, and immunotherapies, specifically tumor-agnostic therapies. This biosimilar mimics the action of the originator drug, pembrolizumab, by targeting and antagonizing the programmed cell death 1 (PD-1) receptor on T lymphocytes. By blocking the interaction between PD-1 and its ligands, RPH 075 enhances T-cell mediated immune responses against cancer cells, promoting antibody-dependent cell cytotoxicity and providing a potent means to counteract tumors. Currently, the drug is in Phase I stage of its clinical trial for the treatment of NSCLC.

The PD-1 Non-Small Cell Lung Cancer pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of PD-1 Non-Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1 Non-Small Cell Lung Cancer Treatment.
* PD-1 Non-Small Cell Lung Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* PD-1 Non-Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PD-1 Non-Small Cell Lung Cancer market.

Get a detailed analysis of the latest innovations in the PD-1 Non-Small Cell Lung Cancer pipeline. Explore DelveInsight's expert-driven report today! @ PD-1 Non-Small Cell Lung Cancer Unmet Needs [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

PD-1 Non-Small Cell Lung Cancer Companies

Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others.

PD-1 Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

PD-1 Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Download DelveInsight's latest report to gain strategic insights into upcoming PD-1 Non-Small Cell Lung Cancer Therapies and key PD-1 Non-Small Cell Lung Cancer Developments @ PD-1 Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the PD-1 Non-Small Cell Lung Cancer Pipeline Report

* Coverage- Global
* PD-1 Non-Small Cell Lung Cancer Companies- Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others.
* PD-1 Non-Small Cell Lung Cancer Therapies- AZD2936, Pembrolizumab 200 mg, Cisplatin, Carboplatin, Durvalumab (MEDI4736 ), and others.
* PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in PD-1 Non-Small Cell Lung Cancer drug development? Find out in DelveInsight's exclusive PD-1 Non-Small Cell Lung Cancer Pipeline Report-access it now! @ PD-1 Non-Small Cell Lung Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) : Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* PD-1 Non-Small Cell Lung Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Zimberelimab: Arcus Biosciences
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* RPH075: R-Pharm
* Preclinical Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Collaborations Assessment- Licensing / Partnering / Funding
* PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Unmet Needs
* PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Market Drivers and Barriers
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pd1-nonsmall-cell-lung-cancer-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies-by-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/oral-electrolyte-solutions-market

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.